4[6]Schneider J.Anoverview of the safety and to leran ceofg lime pirideJ].Horm Metab Res,1996,28:413-418. 被引量：1
5[3]Purrello F,Rabuazza AM.Metabolic factors that affect betacell funciton and survival[J].Diabet Nutr Metab,2000,13:84. 被引量：1
6Purrello F,Rabuazza AM. Metabolic factors that affect betacell funciton and survival[J]. Diabet Nutr Metab,2000,13 : 84- 91. 被引量：1
7Groop LC. Sulfonylureas in NIDDM [J]. Diabetes Care, 1992,15(6) :737. 被引量：1
8Kramer W,Muller G,Geisen K. Characterization of the molecular mode of action of the aulfonylurea,glimepiride, at β-cells [J]. Horm Metab Res, 1996,28:464-468. 被引量：1
9Lormeau B,Aurousseau MH,Valensi P et al. Hyperinsulinemia and hypofibrinloysis : effects of short -- term optimized glycemic control with contineuous insulin infusion in type Ⅱ diabetic patients [J]. Metabolism,1997,46 : 1074- 1079. 被引量：1
10Schneider J. An overview of the safety and tolerance of glimepiride[J]. Horm Metab Res, 1996,28 : 413 - 418. 被引量：1
